Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul;14(7):397-411.
doi: 10.1038/nrgastro.2017.38. Epub 2017 May 10.

Mechanisms of hepatic stellate cell activation

Affiliations
Review

Mechanisms of hepatic stellate cell activation

Takuma Tsuchida et al. Nat Rev Gastroenterol Hepatol. 2017 Jul.

Abstract

Hepatic fibrosis is a dynamic process characterized by the net accumulation of extracellular matrix resulting from chronic liver injury of any aetiology, including viral infection, alcoholic liver disease and NASH. Activation of hepatic stellate cells (HSCs) - transdifferentiation of quiescent, vitamin-A-storing cells into proliferative, fibrogenic myofibroblasts - is now well established as a central driver of fibrosis in experimental and human liver injury. Yet, the continued discovery of novel pathways and mediators, including autophagy, endoplasmic reticulum stress, oxidative stress, retinol and cholesterol metabolism, epigenetics and receptor-mediated signals, reveals the complexity of HSC activation. Extracellular signals from resident and inflammatory cells including macrophages, hepatocytes, liver sinusoidal endothelial cells, natural killer cells, natural killer T cells, platelets and B cells further modulate HSC activation. Finally, pathways of HSC clearance have been greatly clarified, and include apoptosis, senescence and reversion to an inactivated state. Collectively, these findings reinforce the remarkable complexity and plasticity of HSC activation, and underscore the value of clarifying its regulation in hopes of advancing the development of novel diagnostics and therapies for liver disease.

PubMed Disclaimer

References

    1. J Hepatol. 2011 Feb;54(2):366-73 - PubMed
    1. J Hepatol. 2016 Mar;64(3):618-27 - PubMed
    1. Hepatology. 2013 Nov;58(5):1801-13 - PubMed
    1. Nat Med. 2007 Nov;13(11):1324-32 - PubMed
    1. Gastroenterology. 2008 Jan;134(1):248-58 - PubMed

MeSH terms